The canine-specificity of the Gentian Canine CRP Immunoassay

27. Feb 2024 | 6 min read

The canine-specificity of the Gentian Canine CRP Immunoassay

 The Gentian Canine CRP Immunoassay is used for quantitative determination of canine CRP in plasma and serum from dogs. It was developed to offer labs a high-quality assay with a specificity that enables accurate patient results. To achieve this, the reagents include canine-specific antibodies, and the calibrator and controls include canine-specific antigen.

 

Advantages of canine-specific antibodies

Most C-Reactive Protein (CRP) assays for dogs on todays’ market use human CRP antigen in the calibrators and human CRP antibodies in the reagents. The utilisation of canine-specific CRP antibodies ensures the constant reactivity towards canine CRP in the samples, with different antibody batches.

A challenge with the human CRP antibodies is the dependence on the cross-reactivity of the human antibodies with the canine CRP antigen in the samples. The degree of the cross-reactivity of the human antibodies varies and is highly unpredictable from batch to batch.1,2 By including canine-specific antibodies in the manufacturing of the assay the uncertainty of cross-reactivity and variation in results are completely avoided, leading to consistent results, also when switching product lots.

 

Advantages of canine-specific antigen

The canine-specific antigen in the Gentian canine CRP calibrator enables a direct correlation between the calibration curve and the sample results, ensuring the results reflect the real CRP concentration of the canine samples. Assays with human CRP antigen in the calibrator will only report human equivalents of CRP in the canine samples. The human equivalents of CRP can differ from the real canine CRP concentration due to the presence of glycosylation of canine CRP antigen which is not present on the human CRP antigen.3 In addition, the heterogeneity caused by glycosylation of the canine CRP antigen could impact the detection of canine CRP using human CRP antibodies in canine CRP assays.

 

 New call-to-action

 

Gentian cCRP highlights 

The presence of canine-specific components of the Gentian Canine CRP Immunoassay is appreciated by many customers worldwide and contributes to maintaining the high-quality of the assay. It is an open channel assay that can be applied on a wide range of automated clinical chemistry analysers. The assay has been serving the market since 2013.

  • Canine-specific antibodies
    High specificity to the cCRP antigen, low lot variation
  • Avian antibodies
    Reduced interference, no activation of the complement system
  • Calibrator with canine-specific CRP antigen
    Provides results specifically for dogs
  • Fast and accurate results
    Turbidimetric technology, 10 minutes to results
  • Wide measuring range
    ~10 mg/L to 300 mg/L (instrument-dependent)

Canine CRP test


Contact us for more information 

Explore Gentian Canine CRP Immunoassay in your clinical practice or laboratory - fill out the form or send an email to marketing@gentian.com for more information about the product and prices.

 

 

References:

  1. Klenner S et al. Evaluation of three automated human immunoturbidimetric assays for the detection of C-reactive protein in dogs. J Vet Diagn Invest. 2010
  2. Fransson BA et al. Assessment of three automated assays for C-reactive protein determination in dogs. Am J Vet Res. 2007
  3. Caspi D et al. Isolation and characterization of C-reactive protein from the dog. Immunology. 1984

 

This website may contain information about products that are not registered for use in your country of residence and may not comply with applicable laws or regulations in that country. We do not take any responsibility for accessing such information in those circumstances.

You may also read


FAQ: What role has circulating calprotectin in vasculitis?

Apr 17, 2024

FAQ: What role has circulating calprotectin in vasculitis?

Vasculitis and rheumatic diseases Vasculitis is a group of disorders characterised by inflammation of the..

Cystatin C testing - Balancing additional costs against potential benefits

Apr 11, 2024

Cystatin C testing - Balancing additional costs against potential benefits

The KDIGO (Kidney Disease: Improving Global Outcomes) 2024 Clinical Practice Guideline for the Evaluation and..

Scientists to Gentian’s R&D department

Apr 08, 2024

Scientists to Gentian’s R&D department

Scientists to Gentian’s application validation group We are looking for two new colleagues in the positions..